| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 07/16/2002 | US6420414 Amino derivatives of EM-138 and methods of treating angiogenesis with same |
| 07/16/2002 | US6420402 Blocking of associated non-inactivating sodium channels in retinal ganglion cells in order to limit sodium/calcium exchange in retinal ganglion cells and prevent buildup of calcium level in retinal ganglion cells to a lethal level |
| 07/16/2002 | US6420394 Topically applied pharmaceutical formulation |
| 07/16/2002 | US6420355 Hydrophilic organic solvent; mixed mono-, di-, and triglyceride or a transesterified and polyethoxylated vegetable oil; a polyoxyethylene-sorbitan-fatty ester surfactant; emulsion preconcentrate for oral administration |
| 07/16/2002 | US6419963 Composition and method for the treatment of diaper rash using natural products |
| 07/16/2002 | US6419961 Encapsulation;sustained release microcapsulaes |
| 07/16/2002 | US6419960 Oral administering; attention deficit disorder; bead with enteric coating |
| 07/16/2002 | US6419959 Oral administering; side effect reduction |
| 07/16/2002 | US6419958 Extended release formulation of venlafaxine hydrochloride |
| 07/16/2002 | US6419957 Crosslinked with monochloroacetic acid or chloroethylamine hydrochloride |
| 07/16/2002 | US6419956 Odor-masking coating for a pharmaceutical preparation |
| 07/16/2002 | US6419955 Process for making bisphosphonate compositions |
| 07/16/2002 | US6419954 Mixture containing gelled polymer |
| 07/16/2002 | US6419953 Controlled release formulation of divalproex sodium |
| 07/16/2002 | US6419952 Composite wall containing liquid active material |
| 07/16/2002 | US6419951 Sustained releasing drug comprising copolymers and process for preparing the same |
| 07/16/2002 | US6419950 Extracts of zanthoxylum bungeanum, and pharmaceutical and cosmetic formulations containing same |
| 07/16/2002 | US6419949 Microparticles for drug delivery across mucosa and the blood-brain barrier |
| 07/16/2002 | US6419946 Mixture of oil and ester surfactant; moistuizing skin |
| 07/16/2002 | US6419945 Bioerodible insert; for damaged bones |
| 07/16/2002 | US6419940 Analgesics; mixture of triethanolamine, aluminum silicates and methyl red |
| 07/16/2002 | US6419938 Mixture containing fatty acid |
| 07/16/2002 | US6419937 Lipoprotein creams |
| 07/16/2002 | US6419935 Cosmetic skin treatment method and cleansing treatment patch |
| 07/16/2002 | US6419920 Insoluble collagen matrix |
| 07/16/2002 | US6419913 Topical delivery systems for active agents |
| 07/16/2002 | US6419903 Breath freshening film |
| 07/16/2002 | US6419901 Anticancer agents |
| 07/16/2002 | US6419900 Formulation and method for treating neoplasms by inhalation |
| 07/16/2002 | US6419899 Administering drugs |
| 07/16/2002 | US6419709 Biodegradable terephthalate polyester-poly(Phosphite) compositions, articles, and methods of using the same |
| 07/16/2002 | CA2331185A1 Composition for increasing bone density |
| 07/16/2002 | CA2249418C Anticancer drug |
| 07/16/2002 | CA2230097C Stable oil-in-water-emulsion, the procedure involved in its manufacture and its use in cosmetic and dermatological products |
| 07/16/2002 | CA2214097C Use of ketorolac for treatment of squamous cell carcinomas of the oral cavity or oropharynx |
| 07/16/2002 | CA2171738C Parenteral busulfan for treatment of malignant disease |
| 07/16/2002 | CA2165519C P substance antagonist used for the treatment of itching, ocular and/or palpebral algia and ocular and/or palpebral dysesthesia |
| 07/16/2002 | CA2148537C Stable freeze-dried formulation comprising a protein; assay kit |
| 07/16/2002 | CA2131383C Wound healing and treatment of fibrotic disorders |
| 07/16/2002 | CA2125666C Medicaments |
| 07/16/2002 | CA2116956C Pharmaceutical process |
| 07/16/2002 | CA2105977C Thiocarbamate sulfoxide composition for deterring ethanol ingestion |
| 07/16/2002 | CA2052392C Extract from ginkgo biloba leaves, in particular for intravenous injection or infusion, a method of preparation of the extract and ampoule preparations containing the extract |
| 07/16/2002 | CA2037943C Orifice insert for a ruminal bolus |
| 07/11/2002 | WO2002053677A1 Fluorescent ink compositions comprising functionalized fluorescent nanocrystals |
| 07/11/2002 | WO2002053624A1 Crosslinked disulphide containing polymers for drug delivery |
| 07/11/2002 | WO2002053617A1 Linear block polymer |
| 07/11/2002 | WO2002053584A1 Stabilized pharmaceutical composition in lyophilized form |
| 07/11/2002 | WO2002053554A2 Tetraether lipid derivatives and liposomes containing tetraether lipid derivatives and lipid agglomerates and the use thereof |
| 07/11/2002 | WO2002053535A2 Process for making amlodipine, derivatives thereof, and precursors therefor |
| 07/11/2002 | WO2002053525A1 Perfluoronated cycle-containing tertiary amines used as a basis for gas-conveying emulsions and device for the production thereof |
| 07/11/2002 | WO2002053220A2 Low profile pivoting joint infusion assembly |
| 07/11/2002 | WO2002053197A2 Hot melt adhesives for dermal application |
| 07/11/2002 | WO2002053192A1 Stabilised radiopharmaceutical compositions |
| 07/11/2002 | WO2002053190A2 Particles for inhalation having sustained release properties |
| 07/11/2002 | WO2002053187A2 Methods and transdermal compositions for pain relief |
| 07/11/2002 | WO2002053186A2 Fluticasone suspension formulation, spray pattern method, and nasal spray apparatus |
| 07/11/2002 | WO2002053174A2 Controlled release pharmaceutical systems |
| 07/11/2002 | WO2002053168A2 Sterilising pill |
| 07/11/2002 | WO2002053154A1 Pharmaceutical emulsion preparation |
| 07/11/2002 | WO2002053137A2 Pharmaceutical composition for treatment of phimosis using topical corticosteroid |
| 07/11/2002 | WO2002053136A1 Sustained release preparations |
| 07/11/2002 | WO2002053135A1 Amlodipine free base |
| 07/11/2002 | WO2002053134A1 Pharmaceutical compositions comprising amlodipine maleate |
| 07/11/2002 | WO2002053133A1 Pharmaceutical composition containing citalopram |
| 07/11/2002 | WO2002053132A1 Water-soluble powdery or granular compositions based on phenanthridines and their uses |
| 07/11/2002 | WO2002053131A1 Micellar colloidal pharmaceutical compositions containing a lipophilic active principle |
| 07/11/2002 | WO2002053130A2 Sustained release drug delivery devices with coated drug cores |
| 07/11/2002 | WO2002053129A1 Sustained release drug delivery devices with prefabricated permeable plugs |
| 07/11/2002 | WO2002053128A2 Sustained release drug delivery devices with multiple agents |
| 07/11/2002 | WO2002053115A1 Composition used for weaning smokers off the habit |
| 07/11/2002 | WO2002053102A2 Use of iv emulsions with different triglyceride composition, particle size and apolipoprotein e for targeted tissue delivery of hydrophobic compounds |
| 07/11/2002 | WO2002053100A2 Pharmaceutical dosage form for oral administration of low molecular weight heparin |
| 07/11/2002 | WO2002053097A2 Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination |
| 07/11/2002 | WO2002053092A2 Methods employing and compositions containing plaque associated molecules for prevention and treatment of atherosclerosis |
| 07/11/2002 | WO2002053089A2 Stable skin conditioning compositions containing retinoid boosters |
| 07/11/2002 | WO2002052957A1 Creatine/citric acid compound, method for the production of the same and the use thereof |
| 07/11/2002 | WO2002043665A3 Ahf associated dispersion system and method for preparation |
| 07/11/2002 | WO2002039984A3 Medicine based on anti-hyperglycaemic microcapsules with prolonged release |
| 07/11/2002 | WO2002039980A3 Capsule of cellulose derivatives such as hpmc containing benzimidazole derivatives such as omeprazole |
| 07/11/2002 | WO2002038144A8 The use of tiagabine for treatment of diabetic neuropathy and migraine |
| 07/11/2002 | WO2002036737A3 Plant extract that inhibits release of tnf-alpha |
| 07/11/2002 | WO2002026716A3 Benzimidazoles and methods for use thereof in the treatment of cancer or viral infections |
| 07/11/2002 | WO2002019969A3 (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents |
| 07/11/2002 | WO2002017831A3 Devices for intraocular drug delivery |
| 07/11/2002 | WO2002011716A3 Liquid formulation of metformin |
| 07/11/2002 | WO2002003987A3 Pharmaceutical compositions of estrogenic agents |
| 07/11/2002 | WO2001095890B1 Oral pharmaceutical compositions containing terbinafine |
| 07/11/2002 | WO2001091783A3 Methods and compositions for producing a neurosalutary effect in a subject |
| 07/11/2002 | WO2001087262A3 Stabilized steroidal suspension |
| 07/11/2002 | WO2001076593A3 Bile secretion promoting composition a 15-keto prostaglandin |
| 07/11/2002 | WO2001076556A3 Lipid-based drug delivery systems against parasitic infections |
| 07/11/2002 | WO2001045577A3 Intervertebral disc treatment devices and methods |
| 07/11/2002 | WO2001039763A3 Use of methylol-containing compounds for the manufacture of a medicament for the treatment of tumors |
| 07/11/2002 | WO2001030392A3 Delivery of proteins across polar epithelial cell layers |
| 07/11/2002 | WO2001021178A3 Method of treating cognitive dysfunction syndrome in dogs and chewable tablet for dogs |
| 07/11/2002 | WO2001020969A3 Use of ribose to prevent cramping and soreness in muscles |
| 07/11/2002 | WO2001017568A3 Bioconjugation in vivo to pulmonary or blood components |
| 07/11/2002 | WO2001013927A9 Improved topical compositions containing probiotic bacteria, spores, and extracellular products and uses thereof |
| 07/11/2002 | WO2001010430A9 Use of estrogen compounds for prevention and treatment of ischemic damage |